Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 3 (2006), Issue 4 (April)

1. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy.
   Nat Rev Drug Discov, 5(4): 295-309. [Abstract] [Full-text]
2. Impact of TBI on late effects in children treated by megatherapy for Stage IV neuroblastoma. A study of the French Society of Pediatric oncology.
   Int J Radiat Oncol Biol Phys, 64(5): 1424-31. [Abstract] [Full-text]
3. The rapid uptake of concurrent chemotherapy for cervix cancer patients treated with curative radiation.
   Int J Radiat Oncol Biol Phys, 64(5): 1389-94. [Abstract] [Full-text]
4. p38 MAPK turns hepatocyte growth factor to a death signal that commits ovarian cancer cells to chemotherapy-induced apoptosis.
   Int J Cancer, 118(12): 2981-90. [Abstract] [Full-text]
5. Use of hormone therapy and risk of breast cancer detected at screening and between mammographic screens.
   Int J Cancer, 118(12): 3112-7. [Abstract] [Full-text]
6. Effect of clopidogrel premedication in off-pump cardiac surgery: are we forfeiting the benefits of reduced hemorrhagic sequelae?
   Circulation, 113(13): 1667-74. [Abstract] [Full-text]
7. Patient assessments of a hypothetical medical error: effects of health outcome, disclosure, and staff responsiveness.
   Qual Saf Health Care, 15(2): 136-41. [Abstract] [Full-text]
8. Reconcilable differences: correcting medication errors at hospital admission and discharge.
   Qual Saf Health Care, 15(2): 122-6. [Abstract] [Full-text]
9. Preventing drug related morbidity: a process for facilitating changes in practice.
   Qual Saf Health Care, 15(2): 116-21. [Abstract] [Full-text]
10. Building safer systems by ecological design: using restoration science to develop a medication safety intervention.
    Qual Saf Health Care, 15(2): 92-7. [Abstract] [Full-text]
11. Use of a standardized protocol to decrease medication errors and adverse events related to sliding scale insulin.
    Qual Saf Health Care, 15(2): 89-91. [Abstract] [Full-text]
12. Development of the Leapfrog methodology for evaluating hospital implemented inpatient computerized physician order entry systems.
    Qual Saf Health Care, 15(2): 81-4. [Abstract] [Full-text]
13. Pharmacologic issues in geriatric emergency medicine.
    Emerg Med Clin North Am, 24(2): 449-65, viii. [Abstract] [Full-text]
14. Albumin-derived nanocarriers: substrates for enhanced cell adhesive ligand display and cell motility.
    Biomaterials, 27(19): 3589-98. [Abstract] [Full-text]
15. Drug loading onto ion-exchange microspheres: modeling study and experimental verification.
    Biomaterials, 27(19): 3652-62. [Abstract] [Full-text]
16. Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy.
    Br J Cancer, 94(7): 1000-6. [Abstract] [Full-text]
17. A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer.
    Br J Cancer, 94(7): 959-63. [Abstract] [Full-text]
18. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer.
    Br J Cancer, 94(7): 969-75. [Abstract] [Full-text]
19. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy.
    Br J Cancer, 94(7): 1011-5. [Abstract] [Full-text]
20. Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study.
    Br J Cancer, 94(7): 976-81. [Abstract] [Full-text]
21. Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma.
    Blood, 107(8): 3058-64. [Abstract] [Full-text]
22. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation.
    Blood, 107(8): 3065-73. [Abstract] [Full-text]
23. The impact of involved field radiation therapy for patients receiving high-dose chemotherapy followed by hematopoietic progenitor cell transplant for the treatment of relapsed or refractory Hodgkin disease.
    Am J Clin Oncol, 29(2): 189-95. [Abstract] [Full-text]
24. The incidence of potential interactions between dietary supplements and prescription medications in cancer patients at a Veterans Administration Hospital.
    Am J Clin Oncol, 29(2): 178-82. [Abstract] [Full-text]
25. Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity.
    Am J Clin Oncol, 29(2): 171-7. [Abstract] [Full-text]
26. Chemoradiotherapy for adenoid cystic carcinoma: preliminary results of an organ sparing approach.
    Am J Clin Oncol, 29(2): 153-7. [Abstract] [Full-text]
27. Subcutaneous interleukin-2 and interferon-alpha in metastatic renal cell carcinoma: results of a French regional experience in Languedoc.
    Am J Clin Oncol, 29(2): 148-52. [Abstract] [Full-text]
28. A pilot trial of gemcitabine and vinorelbine plus capecitabine in locally advanced or metastatic nonsmall cell lung cancer.
    Am J Clin Oncol, 29(2): 143-7. [Abstract] [Full-text]
29. Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma.
    Am J Clin Oncol, 29(2): 127-31. [Abstract] [Full-text]
30. Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial.
    Am J Clin Oncol, 29(2): 116-22. [Abstract] [Full-text]
31. Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer.
    Am J Clin Oncol, 29(2): 109-15. [Abstract] [Full-text]
32. Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience.
    BMC Cancer, 6: 76. [Abstract] [Full-text]
33. Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer.
    J Clin Oncol, 24(11): 1689-99. [Abstract] [Full-text]
34. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.
    Cancer Chemother Pharmacol, 57(6): 709-18. [Abstract] [Full-text]
35. A phase I study of 3-day topotecan and cisplatin in elderly patients with small-cell lung cancer.
    Cancer Chemother Pharmacol, 57(6): 755-60. [Abstract] [Full-text]
36. Pharmacodynamic properties of methotrexate and Aminotrexate during weekly therapy.
    Cancer Chemother Pharmacol, 57(6): 826-34. [Abstract] [Full-text]
37. A phase I combination chemotherapy study of biweekly paclitaxel and S-1 administration in patients with advanced gastric cancer.
    Cancer Chemother Pharmacol, 57(6): 736-40. [Abstract] [Full-text]
38. Second-line chemotherapy in small cell lung cancer in a modified administration of topotecan combined with paclitaxel: a phase II study.
    Cancer Chemother Pharmacol, 57(6): 796-800. [Abstract] [Full-text]
39. Sequenced combined intravitreal triamcinolone and indocyanine green angiography-guided photodynamic therapy for retinal angiomatous proliferation.
    Arch Ophthalmol, 124(4): 487-92. [Abstract] [Full-text]
40. Venous thrombosis and conjugated equine estrogen in women without a uterus.
    Arch Intern Med, 166(7): 772-80. [Abstract] [Full-text]
41. A prospective study of female hormone use and breast cancer among black women.
    Arch Intern Med, 166(7): 760-5. [Abstract] [Full-text]
42. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with 17-AAG on glioma cell growth.
    Mol Carcinog, 45(5): 288-301. [Abstract] [Full-text]
43. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.
    JAMA, 295(14): 1658-67. [Abstract] [Full-text]
44. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy.
    JAMA, 295(14): 1647-57. [Abstract] [Full-text]
45. Photodynamic efficiency of diethylene glycol-linked glycoconjugated porphyrins in human retinoblastoma cells.
    J Med Chem, 49(8): 2558-67. [Abstract] [Full-text]
46. Evaluation of basic amphipathic peptides for cellular delivery of antisense peptide nucleic acids.
    J Med Chem, 49(8): 2534-42. [Abstract] [Full-text]
47. Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1.
    Oncogene, 25(16): 2304-17. [Abstract] [Full-text]
48. Disseminate and fatal cytomegalovirus disease with thymitis in a naive HIV-patient after early initiation of HAART: immune restoration disease?
    J Clin Virol, 36(1): 13-6. [Abstract] [Full-text]
49. A novel intensive induction therapy for high-risk neuroblastoma utilizing sequential peripheral blood stem cell collection and infusion as hematopoietic support.
    Pediatr Blood Cancer, 46(7): 793-802. [Abstract] [Full-text]
50. Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy.
    J Infect Dis, 193(10): 1437-40. [Abstract] [Full-text]
51. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.
    J Clin Oncol, 24(12): 1940-9. [Abstract] [Full-text]
52. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.
    J Clin Oncol, 24(12): 1898-903. [Abstract] [Full-text]
53. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.
    J Clin Oncol, 24(12): 1892-7. [Abstract] [Full-text]
54. Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy.
    J Clin Oncol, 24(12): 1883-91. [Abstract] [Full-text]
55. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer.
    J Clin Oncol, 24(12): 1839-45. [Abstract] [Full-text]
56. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.
    J Natl Cancer Inst, 98(8): 516-21. [Abstract] [Full-text]
57. Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer?
    J Surg Oncol, 93(6): 485-90. [Abstract] [Full-text]
58. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer.
    J Clin Oncol, 24(12): 1831-8. [Abstract] [Full-text]
59. Oral ondansetron for gastroenteritis in a pediatric emergency department.
    N Engl J Med, 354(16): 1698-705. [Abstract] [Full-text]
60. Children and antibiotics: analysis of reduced use, 1996-2001.
    Med Care, 44(5): I36-44. [Abstract] [Full-text]
61. Trends in prescription drug expenditures by Medicaid enrollees.
    Med Care, 44(5): I27-35. [Abstract] [Full-text]
62. Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1alpha expression, resulting in reduced angiogenesis.
    Oncogene, 25(17): 2509-19. [Abstract] [Full-text]
63. Cardiovascular, anthropometric and neurocognitive features of healthy postmenopausal women: effects of hormone replacement therapy.
    Life Sci, 78(22): 2625-32. [Abstract] [Full-text]
64. Cytoplasmic transduction peptide (CTP): new approach for the delivery of biomolecules into cytoplasm in vitro and in vivo.
    Exp Cell Res, 312(8): 1277-88. [Abstract] [Full-text]
65. Pilot phase II study of weekly chemotherapy with paclitaxel and carboplatin for refractory or relapsed small-cell lung cancer.
    Cancer Chemother Pharmacol, 58(1): 86-90. [Abstract] [Full-text]
66. CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas.
    Cancer Chemother Pharmacol, 58(1): 35-9. [Abstract] [Full-text]
67. Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme.
    Cancer Chemother Pharmacol, 58(1): 129-35. [Abstract] [Full-text]
68. p53 Status does not affect photodynamic cell killing induced by hypericin.
    Cancer Chemother Pharmacol, 58(1): 91-8. [Abstract] [Full-text]
69. 5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice.
    Cancer Chemother Pharmacol, 58(1): 136-42. [Abstract] [Full-text]
70. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment.
    Lancet, 367(9519): 1335-42. [Abstract] [Full-text]
71. The influence of tidal volume on the dynamic variables of fluid responsiveness in critically ill patients.
    Anesth Analg, 102(5): 1511-7. [Abstract] [Full-text]
72. Application of the thrombolysis in myocardial infarction risk index in non-ST-segment elevation myocardial infarction: evaluation of patients in the National Registry of Myocardial Infarction.
    J Am Coll Cardiol, 47(8): 1553-8. [Abstract] [Full-text]
73. Fluid challenge revisited.
    Crit Care Med, 34(5): 1333-7. [Abstract] [Full-text]
74. Passive leg raising predicts fluid responsiveness in the critically ill.
    Crit Care Med, 34(5): 1402-7. [Abstract] [Full-text]
75. Noscapine and diltiazem augment taxol and radiation-induced S-phase arrest and clonogenic death of C6 glioma in vitro.
    Surg Neurol, 65(5): 478-84; discussion 485. [Abstract] [Full-text]
76. Genetic analyses reveal structured HIV-1 populations in serially sampled T lymphocytes of patients receiving HAART.
    Virology, 348(1): 35-46. [Abstract] [Full-text]
77. SAHA-sensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand (TRAIL): mechanisms leading to synergistic apoptosis.
    Int J Cancer, 119(1): 221-8. [Abstract] [Full-text]
78. Socioeconomic status and medication prescription patterns in pediatric asthma in Canada.
    J Adolesc Health, 38(5): 607.e9-16. [Abstract] [Full-text]
79. Comparison of effectiveness and safety of drug-eluting stents versus vascular brachytherapy for saphenous vein graft in-stent restenosis.
    Am J Cardiol, 97(9): 1303-7. [Abstract] [Full-text]
80. Comparison of safety and efficacy of sirolimus-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction.
    Am J Cardiol, 97(9): 1299-302. [Abstract] [Full-text]
81. Control of drug accessibility on functional polyelectrolyte multilayer films.
    Biomaterials, 27(22): 4149-56. [Abstract] [Full-text]
82. Self-assembled supramolecular hydrogels formed by biodegradable PEO-PHB-PEO triblock copolymers and alpha-cyclodextrin for controlled drug delivery.
    Biomaterials, 27(22): 4132-40. [Abstract] [Full-text]
83. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands.
    BJOG, 113(5): 559-68. [Abstract] [Full-text]
84. Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer.
    Cancer, 106(9): 1917-24. [Abstract] [Full-text]
85. An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study.
    Cancer, 106(9): 1908-16. [Abstract] [Full-text]
86. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion.
    Cancer, 106(9): 1990-7. [Abstract] [Full-text]
87. Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation.
    Cancer, 106(9): 1958-66. [Abstract] [Full-text]
88. Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties.
    Cancer Treat Rev, 32(3): 214-28. [Abstract] [Full-text]
89. Mature results from a randomized Phase II trial of cisplatin plus 5-fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas.
    Cancer, 106(9): 1940-9. [Abstract] [Full-text]
90. Sensitivity as outcome measure of androgen replacement: the AMS scale.
    Health Qual Life Outcomes, 4: 23. [Abstract] [Full-text]
91. Validity of a prescription claims database to estimate medication adherence in older persons.
    Med Care, 44(5): 471-7. [Abstract] [Full-text]
92. Photoinactivation of Mycobacteria in vitro and in a new murine model of localized Mycobacterium bovis BCG-induced granulomatous infection.
    Antimicrob Agents Chemother, 50(5): 1828-34. [Abstract] [Full-text]
93. In vitro and in vivo prodrug therapy of prostate cancer using anti-gamma-Sm-scFv/hCPA fusion protein.
    Prostate, 66(8): 858-66. [Abstract] [Full-text]
94. Detection of residual infarct-related coronary artery stenosis and multivessel disease after thrombolysis: comparison between myocardial contrast echocardiography and single photon emission computed tomography.
    J Am Soc Echocardiogr, 19(5): 546-51. [Abstract] [Full-text]
95. Preprocedural statin use is associated with a reduced hazard of postprocedural myonecrosis in patients undergoing rotational atherectomy--a propensity-adjusted analysis.
    Am Heart J, 151(5): 1031.e1-6. [Abstract] [Full-text]
96. Multifaceted intervention to promote beta-blocker use in heart failure.
    Am Heart J, 151(5): 992-8. [Abstract] [Full-text]
97. Missed opportunities in the secondary prevention of myocardial infarction: an assessment of the effects of statin underprescribing on mortality.
    Am Heart J, 151(5): 969-75. [Abstract] [Full-text]
98. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients.
    Cancer Chemother Pharmacol, 58(2): 143-56. [Abstract] [Full-text]
99. Second-line chemotherapy with weekly paclitaxel and gemcitabine in patients with small-cell lung cancer pretreated with platinum and etoposide: a single institution phase II trial.
    Cancer Chemother Pharmacol, 58(2): 203-9. [Abstract] [Full-text]
100. A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors.
     Cancer Chemother Pharmacol, 58(2): 157-64. [Abstract] [Full-text]
101. Biweekly regimen of cisplatin, gemcitabine and vinorelbine for advanced non-small-cell lung cancer.
     Cancer Chemother Pharmacol, 58(2): 266-71. [Abstract] [Full-text]
102. Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency.
     Cancer Chemother Pharmacol, 58(2): 272-5. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.